Review of cetirizine hydrochloride for the treatment of allergic disorders

Bibliography

• NATHAN R, MELTZER E, SELNER J, STORMS W: Prevalence of allergic rhinitis in the United States. I Allergy Clin. Immunol (1997) 99(6):808–812.
   Google Scholar
• MALONEK D, LAWSON K, SMITH D et al.: A cost of illness study of allergic rhinitis in the United States. I Allergy Clin. Immunol (1997) 99:22–27.
   PubMedGoogle Scholar
• STORMS W, MELTZER EO, NATHAN RA, SELNER J: The economic impact of allergic rhinitis. I Allergy Clin. Immunol (1997) 99:S820–S824.
   Google Scholar
• MELTZER EO, GRANT JA: Impact of cetirizine on the burden of allergic rhinitis. Ann. Allergy Asthma Immund (1999) 83(5):455–463.
   PubMedGoogle Scholar
• ••AR causes considerable suffering; however,the degree of suffering generally is poorly appreciated. The economic costs both direct and indirect are discussed in this article.
   Google Scholar
• LEURS R, CHURCH M, TAGLIALATELA M: Hl-antihistamines:inverse agonism, anti-inflammatory actions and cardiac effects. Chit. Exp. Allergy (2002) 17:27–64.
   Google Scholar
• DUBUSKE LM: Second-generation antihistamines: the risk of ventricular arrhythmias. Clin. Ther. (1999) 21(2):281–295.
   PubMed Web of Science ®Google Scholar
• ••Cardiac arrhythmias such as torsades de pointes, as well as other ventricular arrhythmias raised a great deal of concern with respect of second-generation antihistamines. This review of the phenomenon describes evidence that such arrhythmias are not a universal problem with second-generation antihistamines and that cetirizine is free from them.
   Google Scholar
• LEE J, CUMMINS G, OKAMOTO L: A descriptive analysis of the use and cost of new-generation antihistamines in the treatment of allergic rhinitis: a retrospective database analysis. Am. I Manag. Care (2001) 7(4 Suppl.):S103–S112.
   Google Scholar
• LIAO E, LEAHY M, CUMMINS G: The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis. Am. I Manag. Care (2001) 7(15 Suppl.):S459–S468.
   Google Scholar
• SNOWMAN AM, SNYDER SH: Cetirizine: actions on neurotransmitter receptors. I Allergy Clin. Immunol. (1990) 86(6 Pt 2):1025–1028.
   Google Scholar
• SNYDER SH, SNOWMAN AM: Receptor effects of cetirizine. Ann. Allergy (1987) 59(6 Pt 2):4–8.
   Google Scholar
• UCB Pharma SA: cetirizine package insert. UCB Pharma SA, Brussels, Belgium.
   Google Scholar
• GILLARD M, VAN DER PERREN C, MOGUILEVSKY N, MASSINGHAM R, CHATELAIN P: Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). MM. Pharmacy]. (2002) 61(2):391–399.
   PubMed Web of Science ®Google Scholar
• URIEN S, TILLEMENT JP, GANEM B, KUCH MD: A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. J. Clin. Pharmacy]. Ther. (1999) 37(10):499–502.
   Google Scholar
• SPICAK V, DAB I, HULHOVEN R et al.: Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. Clin. Pharmacy]. The]: (1997) 61(3):325–330.
   PubMedGoogle Scholar
• •This study defines the pharmacodynarnic properties of cetirizine in children.
   Google Scholar
• BENEDETTI MS, PLISNIER M, KAISE J et al.: Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Ear: .1. Clin. Pharmacol (2001) 57(8):571–582.
   Google Scholar
• BALTES E, COUPEZ R, GIEZEK H, VOSS G, MEYERHOFF C, STROLIN BENEDETTI M: Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundam. Clin. Pharmacol (2001) 15(4):269–277.
   PubMedGoogle Scholar
• WOOD SG, JOHN BA, CHASSEAUD LF, YEH J, CHUNG M: The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann. Allergy (1987) 59(6 Pt 2):31–34.
   Google Scholar
• PASSALACQUA G, BOUSQUET J, BACHERT C et al.: Position paper: the clinical safety of Hl-receptor antagonists. An EAACI position paper. Allergy (1996) 51:666–675.
   Google Scholar
• HULHOVEN R, DESAGER JP, HARVENGT C: Lack of clinically relevant interaction of cetirizine on theophylline disposition in healthy subjects: a placebo-controlled study. Am. Ther (1995) 2(1):71–74.
   PubMedGoogle Scholar
• SALE ME, WOOLSEY R, THAKKER K et al.: Effects of cetirizine and erythromycin alone and in combination on QT interval and pharmacokinetics in healthy subjects. Ann. Allergy Asthma Immunol (1996) 64:93.
   Google Scholar
• SALE ME, WOOLSEY R, THAKKER K et al.: A randomised, placebo-controlled multiple-dose study to evaluate the electrocardiographic and pharmacokinetic interactions of azithromycin and cetirizine. Ann. Allergy Asthma Immunol (1996) 64:93.
   Google Scholar
• SIMONS FE, SUSSMAN GL, SIMONS KJ: Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the Hl-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. I Allergy Clin. Immunol (1995) 95(3):685–693.
   PubMed Web of Science ®Google Scholar
• DOMS M, VANHULLE G, BAELDE Y, COULIE P, DUPONT P, RIHOUX JP: Lack of potentiation by cetirizine of alcohol-induced psychomotor disturbances. Eur.j Clin. Pharmacol (1988) 34(6):619–623.
   PubMedGoogle Scholar
• SALE ME, BARBEY JT, WOOSLEY RL et al: The electrocardiographic effects of cetirizine in normal subjects. Clin. Pharmacol The]: (1994) 56(3):295–301.
   PubMedGoogle Scholar
• SIMONS FE, WATSON WT, MINUK GY, SIMONS KJ: Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. I Clin. Pharmacol (1993) 33(10):949–954.
   PubMedGoogle Scholar
• HORSMANS Y, DESAGER JP, HULHOVEN R, HARVENGT C: Single- dose pharmacokinetics of cetirizine in patients with chronic liver disease. Clin. Pharmacol (1993) 33(10):929–932.
   Google Scholar
• MATZKE GR, YEH J, AWNI WM, HALSTENSON CE, CHUNG M: Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. Ann. Allergy (1987) 59(6 Pt 2):25–30.
   Google Scholar
• DESAGER JP, DAB I, HORSMANS Y, HARVENGT C: A pharmacokinetic evaluation of the second-generation Hl-receptor antagonist cetirizine in very young children. Clin. Pharmacol Ther. (1993) 53(4):431–435.
   PubMedGoogle Scholar
• PARIENTE-KHAYAT A, REY E, DUBOIS MC et al.: Pharmacokinetics of cetirizine in 2- to 6-year-old children. Int. J. Clin. Pharmacol Ther. (1995) 33(6):340–344.
   PubMedGoogle Scholar
• LEFEBVRE RA, ROSSEEL MT, BERNHEIM J: Single dose pharmacokinetics of cetirizine in young and elderly volunteers. Int. J. Clin. Pharmacol Res. (1988) 8(6):463–470.
   PubMedGoogle Scholar
• SIMONS FE, FRASER TG, MAHER J, PILLAY N, SIMONS KJ: Central nervous system effects of Hl-receptor antagonists in the elderly. Ann. Allergy Asthma Immunol (1999) 82(2):157–160.
   PubMedGoogle Scholar
• CLOUGH GE BOUTSIOUKI P, CHURCH MK: Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. Allergy (2001) 56(10):985–988.
   PubMedGoogle Scholar
• RAMBOER I, BUMTBACEA R, LAZARESCU D, RADU JR: Cetirizine and loratadine: a comparison using the ED50 in skin reactions. I Int. Med. Res. (2000) 28(2):69–77.
   PubMedGoogle Scholar
• GRANT JA, DANIELSON L, RIHOUX JP, DEVOS C: A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy (1999) 54(7):700–707.
   PubMedGoogle Scholar
• GRANT JA, RIETHUISEN JM, MOULAERT B, DEVOS C: A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann. Allergy Asthma Immunol (2002) 88(2):190–197.
   PubMed Web of Science ®Google Scholar
• ANTHES JC, GILCHREST H, RICHARD C et al.: Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur. Pharmacol (2002) 449(3):229–237.
   PubMed Web of Science ®Google Scholar
• FADEL R, RAMBOER I, CHATTERJEE N, RIHOUX JP DERDE MP: Cetirizine inhibits bradykinin-induced cutaneous wheal and flare in atopic and healthy subjects. Allergy (2000) 55(4):382–385.
   PubMedGoogle Scholar
• WILSON AM, ORR LC, SIMS EJ, DEMPSEY OJ, LIPWORTH BJ: Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am. I Respir. Crit. Care Med. (2000) 162(4 Pt 1):1297–1301.
   Google Scholar
• AUBIER M, NEUKIRCH C, PEIFFER C, MELAC M: Effect of cetirizine on bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and asthma. Allergy (2001) 56(1):35–42.
   PubMedGoogle Scholar
• DAY JH, BRISCOE M, RAFEIRO E, CHAPMAN P, KRAMER B: Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann. Allergy Asthma Immunol (2001) 87(6):474–481.
   PubMedGoogle Scholar
• NOONAN MJ, RAPHAEL GD, NAYAK A et al.: The health-related quality of life effects of once-daily cetirizine HC1 in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin. Exp. Allergy (2003) 33(3):351–358.
   PubMedGoogle Scholar
• MURRAY JJ, NATHAN RA, BRONSKY EA, OLUFADE AO, CHAPMAN D, KRAMER B: Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc. (2002) 23(6):391–398.
   PubMedGoogle Scholar
• GILLMAN SA, BLATTER M, CONDEMI JJ et al.: The health-related quality of life effects of once-daily cetirizine HC1 syrup in children with seasonal allergic rhinitis. Clin. Pediatr.(2002)41(9)687–696.
   Google Scholar
• PEARLMAN DS, LUMRY WR, WINDER JA, NOONAN MJ: Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebo-controlled study. Clin. Pediatr. (Phil& (1997) 36(4):209–215.
   PubMed Web of Science ®Google Scholar
• CIPRANDI G, PASSALACQUA G, MINCARINI M, RICCA V, CANONICA GW: Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann. Allergy Asthma Immunol (1997) 79(6):507–511.
   PubMedGoogle Scholar
• DIEPGEN TL: Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr. Allergy Immunol (2002) 13(4):278–286.
   PubMedGoogle Scholar
• ZUBERBIER T, MUNZBERGER C, HAUSTEIN U et al.: Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology (1996) 193(4):324–327.
   PubMedGoogle Scholar
• THARP MD: Cetirizine: a new therapeutic alternative for chronic urticaria. Cutts (1996) 58(1):94–98.
   PubMedGoogle Scholar
• BRENEMAN DL: Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann. Pharmacother (1996) 30(10):1075–1079.
   PubMed Web of Science ®Google Scholar
• LA ROSA M, LEONARDI S, MARCHESE G et al.: Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children. Ann. Allergy Asthma Immunol (2001) 87(1):48–53.
   PubMed Web of Science ®Google Scholar
• RIHOUX JP, MICHEL L, ARNOLD R, KONIG W: Hypothetical mechanisms of action of an Hi-antihistamine in asthma. Int. Arch. Allergy Immunol (1999) 118(2–4)380–383.
   Google Scholar
• MINCARINI M, CAGNONI F, CANONICA GW et al.: Quantitative flow cytometric analysis of the effects of cetirizine on the expression of ICAM-1/ CD54 on primary cultured nasal cells. Allergy (2000) 55(3):226–23i.
   Google Scholar
• GHOSH SK, RAFFERTY P, DE VOS C, PATEL KR: Effect of cetirizine, a potent H1 antagonist, on platelet activating factor induced bronchoconstriction in asthma. Clin. Exp. Allergy (1993) 23 (6) :524–527.
   PubMedGoogle Scholar
• GHOSH SK, DE VOS C, MCILROY I, PATEL KR: Effect of cetirizine on histamine- and leukotriene D4-induced bronchoconstriction in patients with atopic asthma. J. Allergy Clin. Immunol (1991) 87(5):1010–1013.
   PubMedGoogle Scholar
• GHOSH SK, DE VOS C, MCILROY I, PATEL KR: Effect of cetirizine on exercise induced asthma. Thorax (1991) 46(4):242–244.
   PubMedGoogle Scholar
• BRIK A, TASHKIN DP, GONG H Jr, DAUPHINEE B, LEE E: Effect of cetirizine, a new histamine H1 antagonist, on airway dynamics and responsiveness to inhaled histamine in mild asthma. I Allergy Immunol (1987) 80(1):51–56.
   PubMedGoogle Scholar
• TASHKIN DP, BRIK A, GONG H Jr: Cetirizine inhibition of histamine-induced bronchospasm. Ann. Allergy (1987) 59(6 Pt 2):49–52.
   Google Scholar
• BUSINCO L, MARZIALI M, FURCOLO G, MEGLIO P: [From atopic dermatitis to asthma]. Minerva Pediatr. (1997) 49(10):477–481.
   PubMedGoogle Scholar
• NO AUTHORS LISTED: Determinants of total and specific IgE in infants with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child. Pediatr. Allergy Immunol (1997) 8(4):177–184.
   PubMedGoogle Scholar
• NO AUTHORS LISTED: Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Early Treatment of the Atopic Child. Pediatr. Allergy Immunol (1998) 9(3):116–124.
   PubMedGoogle Scholar
• ••The ETAC study was the first largecontrolled trial that demonstrated the possibility that prophylactic use of an antiallergic agent such as cetirizine, may have preventative properties. This highly significant finding requires further investigation to determine whether the results represent a class effect, or whether it is unique to cetirizine and which patients would benefit most from prophylactic treatment.
   Google Scholar
• DE LONGUEVILLE M: What are the candidate groups for pharmacotherapeutic intervention to prevent asthma? Pediatr. Allergy Immunol (2000) 11 (Suppl. 13):41–44.
   Google Scholar
• CIPRANDI G, TOSCA M, PASSALACQUA G, CANONICA GW: Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Ann. Allergy Asthma Immunol (2001) 87(3):222–226.
   PubMedGoogle Scholar
• MANN RD, PEARCE GL, DUNN N, SHAKIR S: Sedation with nnon-sedating" antihistamines: four prescription-event monitoring studies in general practice. Br. Med. J. (2000) 320(7243):1184–1186.
   PubMedGoogle Scholar
• SANNITA WG, CRIMI E, RIELA S, ROSADINI G, BRUSASCO V: Cutaneous antihistaminic action of cetirizine and dose-related EEG concomitants of sedation in man. Eur. Pharmacol (1996) 300(1-2):33–41.
   PubMedGoogle Scholar
• SIMONS FE, SILAS P, PORTNOY J, CATUOGNO J, CHAPMAN D, OLUFADE AO: Safety of cetirizine in infants 6 to 11 months of age: a randomized, doubleblind, placebo-controlled study. I Allergy Clin. Immunol (2003) 111:1244–1248.
   PubMedGoogle Scholar
• •This is the study that resulted in cetirizine being approved for treatment of AR and urticaria in children 6 months. If the drug can be used in such young children, then it is indeed safe.
   Google Scholar
• SIMONS FE: Prospective, long-term safety evaluation of the Hl-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child. Allergy Clin. Immunol (1999) 104(2 Pt 1):433–440.
   Google Scholar
• STEVENSON J, CORNAH D, EVRARD P et al.: Long-term evaluation of the impact of the hl-receptor antagonist cetirizine on the behavioral, cognitive, and psychomotor development of very young children with atopic dermatitis. Pediatr. Res. (2002) 52 (2) : 251–257.
   PubMedGoogle Scholar
• ADELSBERG BR: Sedation and performance issues in the treatment of allergic conditions. Arch. Intern. Med. (1997) 157(5):494–500.
   PubMedGoogle Scholar
• SHAMSI Z, KIMBERS, HINDMARCH I: An investigation into the effects of cetirizine on cognitive function and psychomotor performance in healthy volunteers. Ear: J. Pharmacol (2001) 56(12):865–871.
   Google Scholar
• HAMPEL F, RATNER P, MANSFIELD L, MEEVES S, LIAO Y, GEORGES G: Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann. Allergy Asthma Immunol (2003) 91(4):354–36i.
   Google Scholar
• PORTNOY JM, SIMON SD: Is 3-mm less drowsiness important? Ann. Allergy Asthma Immunol (2003) 91(4):324–325.
   PubMedGoogle Scholar
• CARMELIET E: Effects of cetirizine on the delayed K+ currents in cardiac cells: comparison with terfenadine. Br. J. Pharmacol (1998) 124 (4) :663–668.
   PubMedGoogle Scholar
• DELGADO LF, PFERFERMAN A, SOLE D, NASPITZ CK: Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children. Ann. Allergy Asthma Immune] (1998) 80(4):333–337.
   PubMedGoogle Scholar
• HEY JA, DEL PRADO M, SHERWOOD J, KREUTNER W, EGAN RW: Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneimittelferschung (1996) 46(2):153–158.
   PubMedGoogle Scholar
• CANTANI A, MOCINI V: Antihistaminesand the torsade de point in children with allergic rhinitis. Eur. Rev. Med. Pharmacy] Sci. (2001) 5(4):139–142.
   PubMedGoogle Scholar